

09/14/00

JCS912 U.S. PTO

09-18-00

A

UTILITY PATENT
APPLICATION TRANSMITTAL

(Under 37 C.F.R. §1.53(b))

Docket No.: 237.00

Page 1 of 2

Title: Factor IX/Factor IXa Activating Antibodies and Antibody
Derivatives

Express Mail Label No.: EL524823985US

APPLICATION ELEMENTS

ADDRESS TO: Assistant Commissioner for Patents

Box Patent Application

Washington, D.C. 20231

INVENTORS: Friedrich Scheiflinger, Randolph Kerschbaumer, Falko-
Guenter Falkner, Friedrich Dörner, Hans-Peter SchwarzJCS912 U.S. PTO
09/661992
09/14/00

- ☒ Fee Transmittal Form (Submit an original, and a duplicate for fee processing)
2. ☒ Specification [Total Pages]
3. ☒ Drawing(s) (35 USC §113) [Total Pages (Figs.1-36)]
4. ☐ Signed Declaration [Total Pages]
- a. ☐ Newly executed (original or copy)
- b. ☐ Copy from a prior application (37 CFR §1.63(d))
- i. ☐ **(Note Box 5 below)**
DELETION OF INVENTOR(S)
Signed statement attached deleting inventor named in the prior application, see 37 CFR §§1.63(d)(2) and 1.33(b)
5. ☐ Incorporation By Reference (useable if Box 4b is checked.) entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein
6. ☐ Microfiche Computer Program
7. ☐ Nucleotide and/or Amino Acid Sequence Submission
8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR §3.73(b) Statement ☐ Power of Attorney
10. ☐ English Translation Document
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
14. ☐ Small Entity Statement(s)
15. ☐ Certified Copy of Priority Documents (s)
- 16a. ☐ Cancel in the application original claims before calculating the filing fee
- 16b. ☐ Amend the specification by inserting before the first line the sentence: --This is a Continuation, Divisional, Continuation-in-part, of application filed / /
- 16c. ☐ I hereby verify that the attached papers are a true copy of the latest inventor-signed prior application, including a copy of the oath or declaration showing the original signature or an indication it was Signed. I hereby verify that the papers are a true copy of the latest Signed prior application number / / . And further that all statements made herein of my own knowledge are true; and further that these statements were made with the Knowledge that willful false statements and the like so made are Punishable by fine or imprisonment, or both, under Section 1001 Of Title 18 of the United States Code and that such willful false Statements may jeopardize the validity of the application or any Patent issuing thereon
- 16d. ☐ Other _____
- 16e. ☐ Other _____
17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:
- ☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: /

UTILITY PATENT
APPLICATION TRANSMITTAL

(Under 37 C.F.R. §1.53(b))

Docket No.: 237.00

Page 2 of 2

Title: Factor IX/Factor IXa Activating Antibodies and Antibody Derivatives


Express Mail Label No.: EL524823985US

CLAIMS	(1) FOR	(2) NUMBER	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(b))	24-20 =	4	X \$ 18 =	\$72
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	3	0	\$ 78 =	\$0
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR §1.16(d))			+ \$ 260 =	\$ 0
				BASIC FEE (37 CFR §1.16(a))	\$690
				TOTAL =	\$762

The Commissioner is hereby authorized to credit overpayments or charge the following fees, and any other fees necessary during the pendency of the application, to Deposit Account No. 02 -1437 (Docket R-237.00).
(For this purpose, pursuant to 37 CFR §1.136(a)(3) please incorporate the above authorization into any future reply as a petition for an appropriate extension of time if a petition for an extension of time is not otherwise provided.)

- a. ☒ Fees required under 37 CFR §1.16
- b. ☒ Fees required under 37 CFR §1.17
- c. ☒ Fees required under 37 CFR §1.18

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT


NAME	Michael C. Schiffer, Reg. No. 30,215
SIGNATURE	
DATE	September 14, 2000

CORRESPONDENCE ADDRESS

Baxter Healthcare Corporation
P.O. Box 15210
Irvine, California 92614
Telephone: (818) 550-4569 Fax: (949) 474-6330

CERTIFICATE OF MAILING UNDER 37C.F.R. §1.10

I hereby certify that the above -identified document is being deposited with the United States Postal Service as Express Mail No. EL524823787US in an envelope addressed to Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231 on September 14, 2000.

By: 
Diane M. Branham